<div id="readability-page-1"><p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday following a better than expected earnings announcement. The stock has a 50-day moving average of $15.52 and traded as high as $15.80. Corvus Pharmaceuticals shares last traded at $15.55, with a volume of 980,529 shares traded.</p><div><p><span></span><span>Get <strong>Corvus Pharmaceuticals</strong> alerts:</span></p></div><ul><li>Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026</li></ul><p>The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms recently weighed in on CRVS. Wall Street Zen raised shares of Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 25th. Barclays raised their target price on shares of Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research note on Tuesday, January 20th. Weiss Ratings raised shares of Corvus Pharmaceuticals from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a research note on Wednesday, April 29th. Cantor Fitzgerald  reiterated an &#34;overweight&#34; rating on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Finally, HC Wainwright raised their price objective on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $33.33.</p><p><b>Get Our Latest Analysis on Corvus Pharmaceuticals</b></p><h2>Institutional Investors Weigh In On Corvus Pharmaceuticals</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of CRVS. GSA Capital Partners LLP grew its stake in shares of  Corvus Pharmaceuticals by 25.9% in the 3rd quarter. GSA Capital Partners LLP now owns 401,407 shares of the company's stock worth $2,958,000 after purchasing an additional 82,675 shares during the last quarter.  NEOS Investment Management LLC acquired a new stake in  Corvus Pharmaceuticals during the third quarter valued at approximately $436,000.  SEB Asset Management AB acquired a new stake in  Corvus Pharmaceuticals during the first quarter valued at approximately $3,319,000.  Teachers Retirement System of The State of Kentucky bought a new stake in  Corvus Pharmaceuticals during the first quarter worth approximately $117,000.  Finally, SG Americas Securities LLC grew its position in  Corvus Pharmaceuticals by 76.9% in the first quarter. SG Americas Securities LLC now owns 35,420 shares of the company's stock worth $518,000 after buying an additional 15,399 shares during the last quarter. 46.64% of the stock is currently owned by institutional investors. </p><h2>Corvus Pharmaceuticals Price Performance</h2><p>The company has a market cap of $1.31 billion, a P/E ratio of -29.90 and a beta of 0.94. The company has a fifty day simple moving average of $15.52 and a 200-day simple moving average of $12.83. </p><h2>About Corvus Pharmaceuticals</h2> (Get Free Report)<p>Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.  </p><p>Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Corvus Pharmaceuticals</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRVS

SBIO

<p>Corvus Pharmaceuticals (NASDAQ:CRVS) stock price surpassed its 50-day moving average of $15.52, trading at $15.55 after a disappointing earnings report with an EPS of ($0.15), missing estimates by $0.01. Analysts have mixed views, with seven rating it a Buy and one a Sell. Barclays raised its target price from $16.00 to $28.00, while HC Wainwright set a new target of $27.00. Institutional investors hold 46.64% of the stock, which has a market cap of $1.31 billion and a P/E ratio of -29.90.</p>

Market Beat

Corvus Pharma

iShares Global Healthcare

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Barclays

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above Fifty Day Moving Average  After Earnings Miss